136892-64-3|Ecraprost|butyl 7-((4R,5R)-2-(butyryloxy)-4-hydroxy-5-((S,E)-3-hydroxyoct-1-en-1-yl)cyclopent-1-en-1-yl)heptanoate|-范德生物科技公司

Ecraprost

NMR下载 COA and HPLC MSDS下载
names：
butyl 7-((4R,5R)-2-(butyryloxy)-4-hydroxy-5-((S,E)-3-hydroxyoct-1-en-1-yl)cyclopent-1-en-1-yl)heptanoate
CAS号：
136892-64-3
MDL Number：
MF(分子式)： C28H48O6 MW(分子量)： 480.68
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Ecraprost
英文别名	Ecraprost; AS-013; AS 013; AS013; Circulase; Lipo-pro-prostaglandin E1;
CAS号	136892-64-3
Inchi	InChI=1S/C28H48O6/c1-4-7-11-15-22(29)18-19-23-24(26(21-25(23)30)34-28(32)14-6-3)16-12-9-10-13-17-27(31)33-20-8-5-2/h18-19,22-23,25,29-30H,4-17,20-21H2,1-3H3/b19-18+/t22-,23+,25+/m0/s1
InchiKey	HITYEEHTEOQBAC-OSIGYOHNSA-N
分子式 Formula	C28H48O6
分子量 Molecular Weight	480.68
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Ecraprost(CAS:136892-64-3):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Ecraprost is a prodrug of prostaglandin E1.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Nehler MR, Brass EP, Anthony R, Dormandy J, Jiao J, McNamara TO, Hiatt WR; Circulase investigators. Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. J Vasc Surg. 2007 May;45(5):953-60; discussion 960-[1]Epub 2007 Mar 9. PubMed PMID: 17350216.

[2]Ecraprost: AS 013, Circulase. Drugs R D. 2004;5(1):31-4. Review. PubMed PMID: 14725489.

[3] Brass EP, Anthony R, Dormandy J, Hiatt WR, Jiao J, Nakanishi A, McNamara T, Nehler M; Circulase investigators. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg. 2006 Apr;43(4):752-9. PubMed PMID: 16616232.

[4] Robertson L, Ghouri MA, Kovacs F. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev. 2012 Aug 15;(8):CD002071. doi: 10.1002/14651858.CD002071.pub3. Review. PubMed PMID: 22895926.

[5] Amendt K. PGE1 and other prostaglandins in the treatment of intermittent claudication: a meta-analysis. Angiology. 2005 Jul-Aug;56(4):409-15. PubMed PMID: 16079924.

6: Igarashi R, Takenaga M, Takeuchi J, Kitagawa A, Matsumoto K, Mizushima Y. Marked hypotensive and blood flow-increasing effects of a new lipo-PGE(1) (lipo-AS013) due to vascular wall targeting. J Control Release. 2001 Apr 2;71(2):157-64. PubMed PMID: 11274747.7: Tsutsumiuchi R, Saito H, Imagawa T, Kitamori T, Odake T, Sawada T. In vivo determination of ultratrace amounts of prostaglandin in plasma by high-performance liquid chromatography/laser-induced fluorometry/ultrasensitive laser spectrometry under severe conditions. Anal Chem. 1997 Dec 15;69(24):5006-10. PubMed PMID: 9414614.8: Hokamura K, Umemura K, Nakamura N, Watanabe M, Takashima T, Nakashima M. Effect of lipo-pro-prostaglandin E1, AS-013 on rat inner ear microcirculatory thrombosis. Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):203-7. PubMed PMID: 9844994.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开